M
Memento Medicines
Bispecific antibody therapies for retinal vascular diseases.
About Memento Medicines
Memento Medicines is a Boston-based biotechnology company developing biologic therapies for retinal and vascular diseases. Its lead program, MMT-205 (formerly MT-103), is an investigational bispecific antibody that simultaneously activates the Tie2 receptor and inhibits the VEGF pathway, two clinically validated targets in retinal disease. The company is advancing MMT-205 toward IND-enabling studies in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), with clinical trials expected to begin in 2027. Memento licensed worldwide rights to the asset from MabTics and Curacle, and is one of the subsidiaries financed by Sera Medicines, an antibody accelerator formed with RA Capital Management.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2026
- Headquarters
- Boston, United States
- Open positions
- None listed
- Dealroom signal
- 18.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Ophthalmology, Drug Development, Chronic Disease
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Memento Medicines.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2026 | $93M | $372M | Forbion Capital Partners · Sanofi Ventures · Samsara BioCapital · RA Capital Management | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 OtusOphtaLipid-based technology for treating dry eye disease |
Helsinki, Finland | Operational | — | — | — |
 CuracleOral therapeutics for age-related intractable vascular diseases |
Seoul, South Korea | Operational | |||
 Ascentia Asset ManagementInvestment fund for development-stage biotechnology companies. |
Waltham, United States | Operational | |||
 SEQOVACross-border pharma and biotech asset partnerships. |
Prague, Czechia | Operational | |||
 Lorikeet TherapeuticsInsulin-independent glucose uptake therapies for Type 1 Diabetes. |
Ringwood, Australia | Operational | |||
 Celea TherapeuticsTherapeutics for serious and progressive respiratory diseases. |
Boston, United States | Operational | |||
 Navegador BiosciencesPreclinical drug development programs for clinical success. |
Portugal | Operational | |||
 Ashta TherapeuticsSmall molecule compounds for difficult-to-treat diseases. |
India | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Forbion Capital Partners
RA Capital Management- ACAvego Bioscience Capital
Sanofi Ventures
Samsara BioCapital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Memento Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Memento Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.